BioSyent Schedules Q2 2026 Earnings Release for Aug. 20

BioSyent said it will report second-quarter and first-half 2026 earnings after market close on Thursday, Aug. 20. President and CEO René Goehrum will post a presentation on the results on the company's website the same day, BioSyent said.

The Mississauga, Ontario-based company had 11,312,635 common shares outstanding as of the release. It trades on the TSX Venture Exchange under the symbol RX.

BioSyent is a specialty healthcare company that markets pharmaceutical and oral health products in Canada and internationally. It focuses on acquiring or licensing developed products with a proven track record, according to the company.

The forward-looking statement in the release cited risks tied to clinical trials, product development, revenue, operations, profitability, and regulatory approvals.